Literature DB >> 16510760

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Peter Glusker, Larry Recht, Barton Lane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16510760     DOI： 10.1056/NEJMc052954

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  72 in total

1.  Reversible posterior leukoencephalopathy syndrome and trastuzumab.

Authors:  Hiroyasu Kaneda; Isamu Okamoto; Taroh Satoh; Kazuhiko Nakagawa
Journal:  Invest New Drugs       Date:  2011-06-03       Impact factor: 3.850

2.  Reversible posterior leucoencephalopathy syndrome associated with bortezomib in a patient with relapsed multiple myeloma.

Authors:  Liesbeth M Kager; Marie-Jose Kersten; Raoul Peter Kloppenborg; Rien Van Oers; Bert-Jan Van den Born
Journal:  BMJ Case Rep       Date:  2009-10-12

3.  Diagnostic uncertainty around seizures in advanced malignancy.

Authors:  Demiana Lenzi Lewis-Hanna; Gurjeet Pamma
Journal:  BMJ Case Rep       Date:  2011-12-21

4.  [Acute bilateral loss of vision in posterior reversible encephalopathy syndrome].

Authors:  K S Bonsel; I Oberacher-Velten; K Hufendiek; H Jägle
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

Review 5.  Roles for VEGF in the adult.

Authors:  Arindel S R Maharaj; Patricia A D'Amore
Journal:  Microvasc Res       Date:  2007-04-06       Impact factor: 3.514

6.  Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.

Authors:  Ghassan El Maalouf; Emmanuel Mitry; Alexis Lacout; Astrid Lièvre; Philippe Rougier
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

7.  Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.

Authors:  Franck Bürki; Kattalin Badie; Philippe Bartoli; Pascale Bernard; Jean Louis Montastruc; Haleh Bagheri
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

Review 8.  Neurologic complications of antitumor antibody therapies.

Authors:  Teri N Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

9.  Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.

Authors:  R Sawaya; W Radwan; S Hammoud
Journal:  Med Oncol       Date:  2014-01-03       Impact factor: 3.064

10.  A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors:  R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal:  Gynecol Oncol       Date:  2013-01-13       Impact factor: 5.482
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.